ecgonidine | 484-93-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: ecgonidine
• 英文别名: (5S)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene-2-carboxylic acid；(-)-ecgonidine；(-)-Ecgonidin；Trop-2-en-2-carbonsaeure；(1R)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene-2-carboxylic acid；(1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene-2-carboxylic acid
• CAS: 484-93-5
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: HZGRVVUQEIBCMS-HTRCEHHLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ecgonidine 在 1-氯乙基氯甲酸酯 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 2β-carbomethoxy-3β-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane
  参考文献：
  名称：

  Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging

  摘要：

  It is now accepted that (-)-cocaine binds to specific recognition sites associated with monoamine transporters in the mammalian brain. In this study, several analogs of 3beta-phenyltropane-2beta-carboxylic acid methyl ester were prepared and their potency for inhibiting the binding of [H-3]-3beta-(4-fluorophenyl)tropane-2beta-carboxylic acid methyl ester to primate caudate-putamen was evaluated. The synthesis and binding affinity of 3beta-(3,4-dichlorophenyl)tropane-2beta-carboxylic acid methyl ester, one of the most potent cocaine congeners yet reported, is presented. The feasibility of synthesizing high-affinity ligands for cocaine recognition sites and their suitability as PET imaging ligands for cocaine receptors in vivo is demonstrated.

  DOI：

  10.1021/jm00059a010
• 作为产物：
  描述：

  古卡因 在 盐酸 作用下， 生成 ecgonidine
  参考文献：
  名称：

  用于肽结构功能研究的Fmoc保护的基于托烷的氨基酸

  摘要：

  已经制备了来自烷烃生物碱核的环状氨基酸，并将其掺入合成肽中。这些构象受限的β-氨基酸在开发生物活性肽的新型合成类似物方面具有相当大的潜力。

  DOI：

  10.1016/s0040-4039(97)00500-5

文献信息

• Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates
  申请人：Lu T. Natalie

  公开号：US20050026303A1

  公开（公告）日：2005-02-03

  A monoclonal antibody, and a cell line capable of producing the same, has been produced with the ability to detect the primary metabolites generated from the pyrolysis of smokeable, or “crack”, cocaine. This monoclonal antibody, while being highly specific for anhydroecgonine methyl ester (AEME) and ecgonidine (ECD), does not cross-react at a significant level with the primary cocaine metabolites of powdered or injected cocaine. Also, crack cocaine conjugates capable of evoking an immune response in animals have been produced.

  一种单克隆抗体以及能够产生同种抗体的细胞系已被生产出来，这种抗体能够检测出从可吸烟的或“霹雳”可卡因的热解中生成的主要代谢物。这种单克隆抗体对去氢古柯碱甲酯（AEME）和古柯宁（ECD）具有高度特异性，但与粉状或注射用可卡因的主要代谢物没有显著交叉反应。此外，已经生产出了能够引起动物免疫反应的霹雳可卡因结合物。
• [EN] NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS<br/>[FR] PROMÉDICAMENTS D'AGENTS THÉRAPEUTIQUES LIBÉRANT DE L'OXYDE NITRIQUE
  申请人：SATYAM APPARAO

  公开号：WO2014111957A1

  公开（公告）日：2014-07-24

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the preparation of these nitric oxide releasing prodrugs, to pharmaceutical compositions containing them and to methods of using these prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其中所述药物或治疗剂至少含有一个羧酸基团。发明还涉及制备这些一氧化氮释放前药的方法，包含它们的药物组合物以及使用这些前药的方法。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Crosslinked hyaluronic acid compositions for tissue augmentation
  申请人：Sadozai K. Khalid

  公开号：US20050136122A1

  公开（公告）日：2005-06-23

  A hyaluronic acid (HA) composition includes crosslinked, water-insoluble, hydrated HA gel particles. The HA includes crosslinks represented by the following structural formula: HA—U—R 2 —U—HA The variables are defined herein. A method of augmenting tissue in a subject includes inserting a needle into a subject at a location in the subject that is in need of tissue augmentation, wherein the needle is coupled to a syringe loaded with the HA composition, and applying force to the syringe, to deliver the HA composition into the subject. A method of preparing the HA composition, includes forming water-insoluble, dehydrated crosslinked HA particles, separating the water-insoluble, dehydrated particles by average diameter, selecting a subset of particles by average diameter, and hydrating the subset of dehydrated particles with a physiologically compatible aqueous solution. Another method of preparing the crosslinked HA composition includes crosslinking a precursor of the crosslinked HA with a biscarbodiimide in the presence of a pH buffer and dehydrating the crosslinked HA. Also included is a method of augmenting tissue in a subject that is in need of tissue augmentation. A method of stabilizing crosslinked HA includes hydrating water-insoluble, dehydrated crosslinked HA with a physiologically compatible aqueous solution that includes a local anesthetic, wherein the value of storage modulus G′ for the stabilized composition is at least about 110% of the value of G′ for a non-stabilized composition,. Also included is the stabilized HA composition.

  一种透明质酸（HA）组合物包括交联的、不溶于水的、水合的HA凝胶颗粒。HA包括由以下结构式表示的交联：HA—U—R2—U—HA。变量在此定义。一种在受试者中增强组织的方法包括将针插入受试者体内需要组织增强的位置，其中针连接到装有HA组合物的注射器，并施加力量到注射器，将HA组合物注入受试者体内。一种制备HA组合物的方法包括形成不溶于水的、脱水的交联HA颗粒，通过平均直径分离不溶于水的、脱水的颗粒，通过平均直径选择颗粒的子集，并用生理兼容的水溶液使脱水的颗粒子集水化。另一种制备交联HA组合物的方法包括在pH缓冲剂存在下用双异氰酸酯交联交联HA的前体，并脱水交联HA。还包括一种在需要组织增强的受试者中增强组织的方法。一种稳定交联HA的方法包括用含有局部麻醉剂的生理兼容水溶液水化不溶于水的、脱水的交联HA，其中稳定组合物的存储模量G′的值至少为非稳定组合物G′值的约110%。还包括稳定的HA组合物。
• [EN] PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED ALKALOIDS<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ALCALOÏDES ENRICHIS SUR LE PLAN ÉNANTIOMÈRE
  申请人：CAMBREX KARLSKOGA AB

  公开号：WO2010086612A1

  公开（公告）日：2010-08-05

  There is provided a process for the preparation of a single enantiomer of anhydroecgonine of formula (I), or a salt thereof, in which R1 is as defined in the description. Such single enantiomers may, for example, be useful intermediates in the synthesis of pharmaceuticals, in which the enantioselectivity is important.

  提供了一种制备式(I)的单对映体或其盐的过程，其中R1如描述中定义。这种单对映体可能在制药合成中起到重要作用，其中对映选择性很重要。